论文部分内容阅读
AIM To examine the association of PNPLA3 polymorphisms in chronic hepatitis C patients and development of liver disease spectrum. METHODS Literature was searched systematically from Pub Med/MEDLINE, EMBASE, and Cochrane search engines for full-length articles written in English that examined PNPLA3 polymorphism in chronic hepatitis C(CHC) patients. Studies evaluating the association of PNPLA3 polymorphism spectrum(fatty liver, steatohepatitis, cirrhosis, and hepatocellular carcinoma) of CHC were included. Pooled data are reported as OR with 95%CI. Our study endpoint was the risk of the entire liver disease spectrum including: Steatosis/fatty liver, cirrhosis, and hepatocellular carcinoma in CHC patients with PNPLA3 polymorphisms.RESULTS Of 380 studies identified, a total of 53 studies were included for full-text review. Nineteen on chronic he-patitis C were eligible for analysis. Pooled ORs for rs738409 GG compared to CC and CG among patients with fatty liver was 2.214(95%CI: 1.719-2.853). ORs among advanced fibrosis/cirrhosis were 1.762(95%CI: 1.258-2.468). Similar odds ratios among hepatocellular carcinoma patients were 2.002(95%CI: 1.519-2.639). Pooled ORs for rs738409 GG and CG compared to CC among patients with fatty liver were 1.750(95%CI: 1.542-1.986). Pooled ORs for advanced fibrosis/cirrhosis patients were 1.613(95%CI: 1.211-2.147). All analyses were homogenous and without publication bias except one. The associations were maintained after adjusting for publication bias and heterogeneity. CONCLUSION PNPLA3 polymorphisms have strong association with increased risk and severity of the liver disease spectrum in CHC patients.
AIM To examine the association of PNPLA3 polymorphisms in chronic hepatitis C patients and development of liver disease spectrum. METHODSOLOGY was searched systematically from Pub Med / MEDLINE, EMBASE, and Cochrane search engines for full-length articles written in English that examined PNPLA3 polymorphism in Studies evaluating the association of PNPLA3 polymorphism spectrum (fatty liver, steatohepatitis, cirrhosis, and hepatocellular carcinoma) of CHC were included. Pooled data are reported as OR with 95% CI. Our study endpoint was the risk of the entire liver disease spectrum includes: Steatosis / fatty liver, cirrhosis, and hepatocellular carcinoma in CHC patients with PNPLA3 polymorphisms .RESULTS Of 380 studies identified, a total of 53 studies were included for full-text review. Nineteen on chronic he-patitis C were eligible for analysis. Pooled ORs for rs738409 GG compared to CC and CG among patients with fatty liver was 2.214 (95% CI: 1.719-2.8 ORDS among advanced fibrosis / cirrhosis were 1.762 (95% CI: 1.258-2.468). Similar odds ratios among hepatocellular carcinoma patients were 2.002 (95% CI: 1.519-2.639). Pooled ORs for rs738409 GG and CG compared to CC among patients with fatty liver were 1.750 (95% CI: 1.542-1.986). Pooled ORs for advanced fibrosis / cirrhosis patients were 1.613 (95% CI: 1.211-2.147). All analyzes were homogenous and without publication bias except one. were maintained after adjusting for publication bias and heterogeneity. CONCLUSION PNPLA3 polymorphisms have strong association with increased risk and severity of the liver disease spectrum in CHC patients.